BASF raises its Evonik offer: November 3 results test Evonik stock

Published on 10/27/2026 at 10:24 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Adjusted EBITDA rose 24.00 percent to EUR 630 million in the second quarter. Evonik stock costs EUR 21.16 on October 27, 2026, 0.66 percent below the Xetra close.

Offer, earnings and valuation

BASF raised its Evonik offer to EUR 24.00 per share on October 23, 2026.
Second-quarter adjusted EBITDA rose 24.00 percent to EUR 630 million in the second quarter of 2026.
Evonik stock trades at EUR 21.16 at 10:13 a.m. CET at Lang & Schwarz on October 27, 2026, 0.66 percent below the Xetra close of October 26, 2026.

Evonik, DE000EVNK013, Illustration mit AI erstellt.

Evonik (ISIN DE000EVNK013) was trading at EUR 21.16 at Lang & Schwarz on October 27, 2026, at 10:13 a.m. CET, down 0.66 percent versus the Xetra close of October 26, 2026. MarketScreener reported on October 23, 2026, that BASF had raised its offer for Evonik to EUR 24.00 per share.

Offer sets the strategic backdrop

The proposed EUR 24.00 per-share offer is above the current German quotation, but the spread does not decide the outcome. Evonik had previously rejected a EUR 22.15 offer as too low, according to Boerse Global on October 19, 2026.

The company is also approaching a financial checkpoint. Evonik's investor-relations calendar schedules its third-quarter 2026 report for November 3, 2026, according to the Evonik investor-relations page.

Three figures frame the story

On August 4, 2026, Evonik reported second-quarter revenue of EUR 3,893 million and adjusted EBITDA of EUR 630 million, up 24.00 percent from the prior-year quarter, according to NadirAlpha. The same update said full-year adjusted EBITDA guidance stood at EUR 2.00 billion to EUR 2.20 billion.

The chronology is clear: revenue reached EUR 3,893 million on August 4, 2026, adjusted EBITDA reached EUR 630 million on August 4, 2026, and BASF's offer rose to EUR 24.00 per share on October 23, 2026. Together, the figures put operational recovery and takeover value on the same investor scorecard.

What will the November report clarify?

The November 3 report will show whether the second-quarter improvement carried into the third quarter. Goldman Sachs kept a Neutral rating and a EUR 20.00 target in a report dated October 1, 2026, while forecasting third-quarter adjusted EBITDA of EUR 637 million versus consensus of EUR 624 million, according to Finvaulta. That target is below the current Lang & Schwarz quotation, making the earnings release relevant even as takeover discussions continue.

Dates and valuation remain central

The next substantiated company date is November 3, 2026, the third-quarter reporting date. The investor-relations calendar also lists March 4, 2027, for fourth-quarter 2026 reporting, giving the market a later reference point for the company's earnings path.

Stock stays below its yearly high

Evonik's market capitalization was EUR 9.9 billion as of October 27, 2026. Its 52-week range was EUR 12.49 to EUR 21.84, placing the current quotation EUR 0.68 below the upper end of that range. The stock's modest daily decline keeps the takeover premium and the November earnings figures as separate valuation anchors. Evonik was trading at EUR 21.16 at Lang & Schwarz on October 27, 2026, at 10:13 a.m. CET, 0.66 percent below the Xetra close of October 26, 2026 (EUR 21.30). The further course of trading is shown by the continuously updated real-time quote of Evonik stock.